Prollenium US

Prollenium US is the American branch of Prollenium Medical Technologies, a Canadian company founded in 2002. It specializes in the research, development, manufacturing, and distribution of medical aesthetics products, particularly dermal fillers. The company is known for its Revanesse product line, which features cross-linked hyaluronic acid (HA) dermal fillers designed for facial aesthetics, including wrinkle reduction and volume restoration. Prollenium was the first to receive FDA approval for injectable dermal fillers in the US in 2017. The company operates its own manufacturing facilities in Canada, ensuring high-quality standards with rigorous quality control for each product. Prollenium's research and development team focuses on enhancing HA formulations and cross-linking technology, collaborating with healthcare professionals to meet clinical needs. Their products are primarily marketed to medical professionals such as dermatologists and plastic surgeons, emphasizing safety, effectiveness, and innovative formulations. Prollenium is dedicated to building strong relationships with customers and advancing the field of facial aesthetics.

• Employees 90
• Founded 2016